Results 241 to 250 of about 379,230 (325)

Lamivudine and tenofovir pharmacokinetic variability in people with HIV in Papua New Guinea

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Demographics and kidney function contribute to variability in lamivudine and tenofovir drug concentrations. The aim was to assess, for the first time, the pharmacokinetic variability of lamivudine and tenofovir in Papua New Guinean (PNG) HIV/AIDS patients.
Natália Bordin Andriguetti   +4 more
wiley   +1 more source

Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Concomitant treatment of tuberculosis (TB) and human immunodeficiency virus (HIV) is complicated by drug‐drug interactions (DDI). This analysis aimed to characterize the DDI between ritonavir‐boosted atazanavir (ATV/r) and rifampicin in plasma and peripheral blood mononuclear cells (PBMC).
Allan Kengo   +10 more
wiley   +1 more source

Biodiversity Credits: An Overview of the Current State, Future Opportunities, and Potential Pitfalls

open access: yesBusiness Strategy and the Environment, EarlyView.
ABSTRACT Biodiversity credits are an emerging vehicle for pro‐environmental financing, yet much uncertainty remains around how and when they could boost biodiversity conservation. Here we define what biodiversity credits are and explore impact pathways through a proposed theory of change. Based on evidence from 34 pilot projects and a review of lessons
Sven Wunder   +16 more
wiley   +1 more source

Between Substance and Symbolism: How Resources and Organizational Facades Interact in Voluntary Climate Commitments

open access: yesBusiness Strategy and the Environment, EarlyView.
ABSTRACT Firms increasingly disclose their climate action strategies through voluntary initiatives, yet concerns persist about the substantive impact of such disclosures. This study investigates how internal resources interact with organizational facades—symbolic mechanisms designed to reinforce legitimacy to stakeholders—in shaping corporate climate ...
David Tobón‐Orozco   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy